arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

download Export Data

Alzamend Neuro, Inc.

ALZN

$1.38 0.00 (0.00%) at close

8 Visible periods

19 Metrics

Absolute Benchmarks

Price Chart

Health

Poor

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Alzamend Neuro, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and Interest Coverage. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $4.6M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -314.8% ↘

FCF / Share $-2.42 ↗

Trailing P/E —

Price / Book 2.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-8.77M

↓ -94.3% —

FCF / Share Free cash flow per share

$-2.42

↑ +83.4% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -314.8% is weak on an absolute basis (target > 10%)
Interest CoverageInterest Coverage of -1324.50x is weak on an absolute basis (target > 5x)
FCF / Net IncomeFCF / Net Income of 0.92x is caution on an absolute basis (target > 1x)

Health Breakdown

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗
EPS Growth YoY (%)	76.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	91.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-88120.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-7.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-94.3% Weak ↓ Weak Declining Year-over-year change in net income	54.6% Excellent ↑ Excellent Improving Year-over-year change in net income	33.1% Excellent ↑ Excellent Improving Year-over-year change in net income	-20.4% Weak ↑ Weak Improving Year-over-year change in net income	-145.0% Weak Weak Year-over-year change in net income	-14.4% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	83.4% Excellent Excellent Year-over-year change in free cash flow	—	—	-23.3% Weak Weak Year-over-year change in free cash flow	-98.9% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗
FCF / Net Income (x)	0.92x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.45x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.54x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.54x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.53x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗
Return on Invested Capital (%)	-314.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-89.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	302.6% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-385.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-72.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-194.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-425.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-421.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-97.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-1573.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-251.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-84.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-170.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-243.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	-113.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-859%)	—	—	-92.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-717%)	-250.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1771%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗
Interest Coverage (x)	-1324.50x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-249.42x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-983.83x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1930.98x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-264.80x Weak Weak Operating income divided by interest expense Optimal: > 5x	-34.77x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-710.69K	$-3.95M	$-376.05K	$-5.14M	$-14.06M	$-1.93M	$-90.28K	$-42.61K

📊 What does each share earn? 5 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-2.63	$-11.32	$-132.33	$-0.15	$-0.14	—	—	—
Free Cash Flow per Share (USD)	$-2.42	$-14.57	—	$-0.09	$-0.07	$-0.04	—	—
Book Value per Share (USD)	$0.52	$5.10	—	$0.03	$0.14	$0.03	$0.01	—
Tangible Book Value per Share (USD)	$0.52	$5.10	—	$0.03	$0.14	$0.03	$0.01	—
Basic Weighted Avg Shares (shares)	3.34M	450,799	74,174	97.52M	89.10M	72.65M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗
Working Capital (USD)	—	—	—	$2.97M	$13.25M	$2.01M	$821.71K	—
Total Equity (USD)	$2.20M	$3.97M	$-2.59M	$3.05M	$13.35M	$2.01M	$821.71K	$316.92K

📋 What is driving earnings? 3 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗
Depreciation Expense (USD)	$110.74K	$50.74K	$50.74K	$23.07K	$3.55K	—	—	—
Net Income, GAAP (USD)	$-8.77M	$-4.51M	$-9.95M	$-14.88M	$-12.36M	$-5.05M	$-4.41M	—
Operating Cash Flow (USD)	$-8.07M	$-6.57M	$-8.27M	$-8.92M	$-6.61M	$-2.71M	$-2.35M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 26 quarters

Alzamend Neuro, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare ALZN with peers